Physician profile
Nicholas D Panting
NPI 1346865516
$1,784.81
in general payments reported to CMS, 2019-2025
23 companies · $595 in 2025
The $595 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $181 · 2024: $1,009 · 2025: $595.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,785.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,784.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $495.40 | 2023-2025 | |
| Supernus Pharmaceuticals, INC. | $295.64 | 2023-2024 | Qelbree, Qelbree |
| Pfizer INC. | $129.74 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $107.84 | 2024-2025 | Caplyta |
| Lilly USA, LLC | $103.18 | 2023-2025 | Mounjaro, Zepbound, Trulicity |
| Novo Nordisk INC | $99.14 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $65.34 | 2024-2025 | Trelegy Ellipta, Penmenvy |
| Takeda Pharmaceuticals U.S.A., INC. | $56.81 | 2024-2025 | Glassia, Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $50.11 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $47.12 | 2024 | Rexulti |
| Lundbeck LLC | $38.10 | 2023-2024 | Rexulti |
| Ethicon INC. | $36.70 | 2024 | Monarch Platform |
| Abbott Laboratories | $36.17 | 2024 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $32.33 | 2024 | Airsupra |
| Exact Sciences Corporation | $31.27 | 2023-2024 | Cologuard Collection Kit |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $31.19 | 2024-2025 | Evenity, Prolia, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.45 | 2025 | Xifaxan |
| Amneal Pharmaceuticals LLC | $21.72 | 2024 | Unithroid |
| Astellas Pharma US INC | $20.88 | 2024 | Veozah |
| Dexcom, INC. | $18.44 | 2023 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.51 | 2025 | Jardiance |
| Axsome Therapeutics, INC. | $14.04 | 2024 | Auvelity |
| Janssen Pharmaceuticals, INC | $13.69 | 2023 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Panting listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.